Insomnia is among the most common sleep disorders worldwide, and its consequences reach well beyond a rough morning. People with insomnia struggle to fall asleep, to stay asleep through the night, or to wake feeling genuinely refreshed, and the disorder can severely degrade quality of life. Perhaps most importantly, chronic insomnia leaves people substantially more vulnerable to developing anxiety and depression over time, making effective treatment a genuine public health priority. Existing options include cognitive behavioural therapy, which is often recommended as a first-line approach, alongside pharmacological treatments such as antidepressants and antipsychotics, but the success of these interventions varies considerably from patient to patient. It is against this backdrop of imperfect alternatives that interest in medical cannabis has surged.

In clinical settings, medical cannabis is not the same product that consumers encounter in dispensaries. Prescribed cannabis medicines typically involve controlled, laboratory-tested ratios of the two best-known cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), delivered in standardised forms such as tablets, sprays or oils. This standardisation is intended to give clinicians predictable doses and compositions. Anecdotal reports and marketing have long touted cannabis as a sleep aid, and the drug’s sedating reputation has made it an appealing candidate for people desperate for rest. Yet the use of medical cannabis for insomnia remains contentious among sleep researchers and clinicians, and the formal evidence base has been thin.

To resolve that uncertainty, the review team systematically assembled the available randomised evidence. The review included nine studies involving 537 adults aged 18 to 76 who were treated for insomnia. Most of the studies focused on people with primary insomnia rather than insomnia linked to other health conditions, a distinction that matters because comorbid insomnia is often harder to treat and mechanistically different. Eight of the nine trials compared regulated medical cannabis against a placebo, the gold-standard design for determining whether a treatment outperforms expectation effects. The ninth trial took a different approach, comparing medical cannabis against amitriptyline, an antidepressant with sedating properties that is sometimes used off-label for sleep.

The headline result is stark in its modesty. Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time, or daytime functioning compared with placebo. In other words, on the outcomes that matter most to patients with insomnia, how well they slept and how they functioned during the day, the drug did not demonstrate a clear advantage over an inert comparison. For a treatment whose reputation rests almost entirely on its perceived sleep benefits, this is a significant setback, and it suggests that the anecdotes driving cannabis’s popularity may not survive the scrutiny of controlled trials.

Safety signals added further concern. Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as dry mouth and dizziness, than those receiving placebo. These effects are not dangerous in the way that some drug side effects can be, but they are not trivial for patients weighing whether a treatment is worth taking. Importantly, the review authors note that this safety conclusion was based on a small pool of studies, which means the true rate of adverse events remains imperfectly characterised. Even so, a treatment that shows no clear benefit while increasing the likelihood of side effects faces an unfavourable risk-benefit calculus.

There was one apparent bright spot: medical cannabis somewhat improved quality of life in the pooled analyses. But the reviewers urge heavy caution here. The certainty of this finding was rated very low, and the pooled results were compatible with anything from a slight worsening to a large improvement. That enormous range of plausible effects is a hallmark of unreliable evidence, and it means patients and clinicians cannot reasonably conclude from this dataset that cannabis genuinely enhances quality of life for people with insomnia. The finding is best read as a signal of what better-designed trials might one day examine, rather than as a positive result in its own right.

Why is the evidence so shaky? The review team graded the overall quality and certainty of the evidence as very low to low, and the reasons are instructive for anyone trying to interpret medical research headlines. The underlying studies carried a high risk of bias, meaning flaws in their design or conduct may have distorted their results. Findings were inconsistent between trials, making it hard to generalise from any single study. Sample sizes were small, with the entire review resting on 537 participants across nine trials. The studies also varied considerably in the type of cannabis product used, which limited comparability across trials, since different formulations, cannabinoid ratios and delivery methods can plausibly produce different effects. Perhaps most limiting of all, the longest study followed participants for only 12 weeks, leaving the long-term effects of cannabis treatment for insomnia essentially unknown.

There is also a representativeness problem that the reviewers highlight. The available data were heavily skewed towards younger people and women, who made up 72.66 percent of participants. As a result, the findings may not apply as well to men, to older adults, or to people with comorbid health conditions, groups that represent a large share of real-world patients seeking treatment for sleep problems. Clinicians hoping to use this evidence to guide prescribing for an older patient with multiple health issues will find that the trials simply did not include enough people like them to say anything confident. This gap between trial populations and clinical populations is a recurring weakness in cannabis research, and it is one the review makes impossible to ignore.

The authors’ conclusion is measured but firm: the evidence remains weak and uncertain, and higher-quality research is needed before medical cannabis can be recommended for insomnia. Dr Lucia Varela, lead author of the study from the University of Manitoba in Canada, emphasised that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia, adding that this does not mean the treatment is ineffective, but that based on current evidence no reliable conclusions about its effectiveness can be drawn for the general population. Dr Luis Garegnani, senior author from the Universidad Hospital Italiano de Buenos Aires in Argentina, advised that rather than viewing the findings as an endorsement or a rejection of medical cannabis, clinicians and patients should recognise the uncertainty and consider individual circumstances while better evidence is generated. All authors declared no commercial or non-commercial conflicts of interest relevant to the review. For now, the message for the millions of people struggling with sleepless nights is not that cannabis cannot work, but that no one yet knows whether it does, and the only honest response to that uncertainty is more rigorous science.

Subject of Research: Medical cannabis as a treatment for insomnia

Article Title: Insufficient evidence to back medical cannabis for insomnia

Article References: Insufficient evidence to back medical cannabis for insomnia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: medical cannabis, insomnia, Cochrane review, sleep quality, THC, CBD, systematic review, placebo, evidence quality, sleep disorders, clinical trials, daytime functioning